INNOVENT BIO(01801) issued 1,935,600 share options and 10,241,300 restricted shares.

08:19 31/03/2026

Sinobioway Biomedicine (01801) announced that on March 30, 2026, the company granted 1.9356 million stock options to 66 grantees (including directors) in accordance with the terms of the 2024 share plan, and granted 10.2413 million restricted shares to 1308 grantees, subject to acceptance by the grantees.

INNOVENT BIO (01801) announces that on March 30, 2026, the company has granted 1,935,600 stock options to 66 grantees (including directors) in accordance with the terms of the 2024 share plan, and has also granted 10,241,300 restricted shares to 1,308 grantees, subject to their acceptance.

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.